Immunotherapy plus radiation before surgery for liver cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests whether combining the immunotherapy drug sintilimab with targeted radiation therapy before surgery can improve outcomes for patients with liver cancer that can be surgically removed. It aims to shrink the tumor and reduce the chance of recurrence.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- Your liver cancer must be at an early or intermediate stage and can be removed with surgery.
- You must have good overall health (ECOG score 0-1) and adequate liver function (Child-Pugh score 7 or less).
- You cannot have received any prior cancer treatment for liver cancer.
- You must not have cancer that has spread outside the liver.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if combining three therapies (sintilimab, lenvatinib, and HAIC) before surgery can help shrink liver tumors that are on the borderline of being removable. It's for people whose cancer has spread into nearby blood vessels but not to other organs.
This Phase 2 trial tests whether combining targeted liver procedures (TACE) and high-dose radiation (SBRT) followed by two immunotherapy drugs can “downstage” hepatocellular carcinoma (HCC), meaning make it smaller/less advanced. It may help some people become better candidates for future treatment by shrinking tumors.
This trial tests a combination of focused radiation (SBRT), an immunotherapy drug (adelimumab), and a targeted therapy pill (apatinib) before surgery for liver cancer. The goal is to shrink tumors enough to make surgery possible or more effective.
This trial tests combining an immunotherapy drug (sintilimab) with focused radiation (SBRT) before surgery for liver cancer that has spread into a branch of the portal vein. The goal is to see if this combination can shrink the tumor and make surgery more successful.
This study tests whether adding two immunotherapy drugs (durvalumab and tremelimumab) plus radiation before surgery works better than radiation alone before surgery for people with resectable liver cancer. It's for those with a single tumor (or a few small nearby spots) that hasn't spread.
This trial tests a combination of targeted radiation (SBRT) and immunotherapy for people with small liver cancers that have come back or are still present after prior treatment. It aims to see if this approach can better control the cancer without using heavy chemotherapy.
Hear when a new HCC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.